Vice President, Lilly Research Labs Operations
Andrew Dahlem was named vice president of operations for Lilly Research Laboratories in February 2007. He is a member of the senior management council. He had been vice president of toxicology, drug disposition, pharmacokinetics, and Lilly Research Laboratories in Europe since January 2003.
He received a bachelor of science degree in wildlife biology from The Ohio State University in 1982 and a doctor of philosophy degree in toxicology from the University of Illinois at Urbana-Champaign in 1989.
Dahlem joined Lilly in 1990 as a senior pharmacologist. He became head of biochemical toxicology in 1992. He was named director of drug disposition and biochemical (investigative) toxicology in 1993. He was promoted to executive director for toxicology and drug disposition in 1998, and he assumed responsibility for LRL in Europe in 1999 and for discovery operations in 2000. In December 2001 he was promoted to Vice President.
He is a member and past president of Indianapolis/Cincinnati Discussion Group of the American Association of Pharmaceutical Scientists. He is also a member of the International Society for the Study of Xenobiotics, the Society of Toxicology, and the American Association for the Advancement of Science.
Dahlem serves as adjunct professor of toxicology in the College of Veterinary Medicine at Purdue University, the University of Illinois at Urbana-Champaign, and at The Ohio State University. He is also a member of the University of Washington School of Pharmacy Corporate Advisory Board. Dahlem currently serves as chair of the PhRMA Preclinical Safety Leadership Committee (DruSafe). He is also a member of the Pharmaceutical Innovation Steering Committee (PISC) and co-leads a PhRMA/PISC working group on Predictive Models of Safety, Efficacy, and Compounds Properties.
